A blood-based layer for the most common cancer in Hong Kong, where driver mutations, never-smokers and rapid resistance all make a single protocol a poor fit.
Hong Kong context Lung cancer was the most common cancer in Hong Kong in 2023, with 6,111 new cases (3,576 in men, 2,535 in women) and the leading cause of cancer death. A large share of local cases occur in never-smokers, especially among women, which is a different biology from classic smoking-related squamous disease. |
Why this cancer is hard to manage with a single protocol
Modern lung-cancer care is already personalised at the mutation level: EGFR, ALK, ROS1, BRAF, MET, RET, KRAS G12C, NTRK, PD-L1. That is necessary and still incomplete. Tissue NGS tells you which target exists. It does not tell you whether the circulating cells are still dependent on that target, or which chemotherapy backbone will work when the TKI fails.
Repeat tissue biopsy of a progressing lung lesion is not always safe or possible. Liquid biopsy is already standard for EGFR T790M and other resistance mutations via ctDNA. CTC analysis is the other half of that idea: not only the DNA fragments the tumour sheds, but the living cells themselves, their phenotype, stemness and drug response.
Early disease is still found late. Low-dose CT helps selected smokers. It does not solve the never-smoker population that drives so much of Hong Kong’s female lung-cancer burden.
What circulating tumor cells add
Oncotrail RGCC includes a lung panel. It is intended for patients with a confirmed diagnosis, to benchmark CTC burden and activity and to track the current management plan. RGCC sample materials include a lung-specific reference range for CTC count.
Onconomics Plus then asks a different question: against these isolated cells, which cytotoxic agents, targeted drugs and natural compounds induce apoptosis, and which resistance factors are expressed? That is particularly relevant at TKI progression, after chemo-immunotherapy, or when the patient is not a candidate for another biopsy.
The RGCC pathway for this cancer
A typical sequence is screening or baseline first, then a comprehensive profile when treatment choices matter, then serial follow-up. The exact panel is chosen by the accredited practitioner.
Clinical question | RGCC test to consider |
No diagnosis; high concern (family history, never-smoker with symptoms, inconclusive imaging) | Onco-D-clare as an adjunct — it does not replace CT or bronchoscopy |
Confirmed lung cancer; baseline and monitoring | Oncotrail RGCC (lung panel) |
Choosing or changing systemic therapy, including after TKI failure | Onconomics Plus |
Need FDA-linked mutational / immunotherapy context from CTCs | CAMBISeq (NGS on CTC-derived nucleic acids) |
Drug-handling variants before a toxic regimen | ChemoSNiP |
Burden-only interval check | Oncocount |
What the report can change in practice
Read the CTC report next to the latest CT and the latest ctDNA panel, not instead of them. A falling CTC count during a TKI or chemo-IO plan supports staying the course. A rising count with changing phenotype, while the scan still looks stable, is a reason to look for oligoprogression or a new clone.
Onconomics Plus is most useful when guidelines offer several reasonable next lines and the patient cannot tolerate another blind cycle. It is also the cleanest way to discuss integrative agents without guessing.
Small-cell lung cancer behaves differently from NSCLC. The same blood-test logic applies — living cells in blood, serial counts, functional sensitivity — but interpretation must stay with a clinician who treats SCLC regularly.
Who this article is for
• Newly diagnosed NSCLC or SCLC, before the first systemic line.
• Patients progressing on a TKI or on chemo-immunotherapy.
• People who cannot safely repeat a tissue biopsy.
• Never-smokers under investigation, as part of a wider work-up — not as a stand-alone screen.
• Survivors in follow-up who want an additional surveillance tool between scans.
Next step
Bring your latest CT report, any EGFR / ALK / NGS results, and a list of drugs already used. An RGCC-accredited practitioner will decide whether Oncotrail, Onconomics Plus, CAMBISeq, or a combination is the right blood draw at this visit.
Disclaimer. This article is educational and is intended for patients, families, and referring practitioners. RGCC tests are laboratory investigations that support clinical decision-making. They do not replace imaging, tissue diagnosis, or a treating oncologist’s judgement. Results must be interpreted by an RGCC-accredited practitioner in the context of the full medical history. RGCC circulating tumor cell (CTC) assays are not designed to detect primary cancers of the brain or central nervous system. Always discuss findings with your own doctor before changing any treatment.